CoviVac Russia COVID-19 Vaccine Description
CoviVac Russia COVID-19 Vaccine is a whole-virion vaccine that uses viruses that have already been killed (inactivated). CoviVac-Russia vaccine includes all the elements of the virus.
The CoviVac-Russia is a two-shot vaccination and is recommended for use from 18 to 60 years old.
According to the general director of the Chumakov Center, Aydar Ishmukhametov, none of the international companies working on this method of obtaining vaccines has yet released whole virion vaccines against COVID-19. “I am sure that six months later, maybe earlier, all the same, whole-virion vaccines will dominate in the same way as it happened in other types of vaccines, in other developments,” reported Medexpert.ru on February 20, 2021.
Only the Chumakov Center is indicated as a manufacturer in the vaccine registration certificate. The Chumakov Center was established in 1955 as the Institute of Poliomyelitis and Viral Encephalitis, which combined research laboratories with vaccine manufacturing facilities. The Center was created by Dr. Mikhail Chumakov, who, at the end of the 1950s, organized the first production of oral polio vaccine from strains developed by Dr. Albert Sabin and demonstrated its safety and effectiveness.
CoviVac Russia COVID-19 Vaccine Indication
CoviVac Russia COVID-19 Vaccine is indicated to prevent COVID-19, which the SARS-CoV-2 coronavirus causes. The CoviVac vaccine is recommended for persons aged 18 to 60.
CoviVac Russia COVID-19 Vaccine News
February 20, 2021 - According to Reuters, Russia's Prime Minister Mishustin stated the CoviVac-Russia vaccine had been registered, becoming the third Russian coronavirus vaccine.
December 22, 2021 - TASS reported the Chumakov Federal Scientific Center for Research and Development of Immune and Biological Products of the Russian Academy of Sciences would apply to register its COVID-19 vaccine in early 2021.
October 20, 2020 - Chumakov Center initiates Covid-19 vaccine candidate trials. The trials will take place at Eco-Safety Research Center on 30 healthy volunteers aged between 18 and 45 years who tested negative for Covid-19 and the absence of antibodies to the virus.
October 6, 2020 - Trials of a whole-virion inactivated vaccine developed by the Chumakov Center commenced in Novosibirsk, reported Russian news agency Tass. Tass quoted Eco-Safety Research Center deputy chief Konstantin Zakharov saying: “The volunteers will be hospitalized for 16 days. We will use the vaccine twice – today and in 14 days.
August 23, 2020 - “Today, we have sent all the necessary documents to the Ministry of Health of the Russian Federation to conduct full clinical trials of a vaccine against COVID-19. We are waiting for permission to conduct them and expect to complete clinical trials in October this year. We plan that more than 3 thousand people will take part in the tests, which will meet the requirements of the World Health Organization and other international regulators, ”said the director of the Chumakov center.
"Our center is working on the creation of a whole-virion inactivated vaccine against coronavirus. From our perspective, working with such a vaccine is correct because there is no data yet on which fragments of the virus to use correctly. Secondly, the technology of creating whole-virion vaccines has been successfully used for several decades. We plan to complete preclinical trials of our own vaccine by early August, and in January 2021, after the successful completion of clinical trials, it will be possible to talk about a large-scale release of the vaccine, for the organization of which we have our own production, "he said.
Previously, the Poliomyelitis Institute successfully conducted preclinical trials of its own whole virion vaccine against COVID-19. Whole-virion vaccines use viruses that have already been killed (inactivated).
“Preclinical studies of our vaccine have shown a strong immune response. After the successful completion of clinical trials, the mass production of our vaccine can be launched already in November this year, ”emphasized Aydar Ishmukhametov.